This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Acadia Healthcare to Report Q4 Earnings: Can it Overcome Rising Costs?
by Zacks Equity Research
ACHC's fourth-quarter earnings are likely to have benefited from growing patient days and admissions.
Universal Health to Report Q4 Earnings: What Do the Estimates Say?
by Zacks Equity Research
UHS' fourth-quarter earnings are likely to have benefited from growing admissions and patient days.
Select Medical Q4 Earnings Miss Estimates, Stock Down 7.2%
by Zacks Equity Research
SEM expects revenues to be between $5.4 billion and $5.6 billion, the mid-point of which implies 5.8% growth from the 2024 figure of $5.2 billion.
Why HCA Healthcare (HCA) is a Top Stock for the Long-Term
by Zacks Equity Research
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Community Health Q4 Earnings Miss on Lower Adjusted Admissions
by Zacks Equity Research
CYH expects 2025 capital expenditures to be in the range of $350-$4000 million.
Pediatrix Medical Gears Up for Q4 Results: What to Expect?
by Zacks Equity Research
MD's fourth-quarter results are likely to reflect declining revenues and expenses.
Why HCA Healthcare (HCA) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Can Community Health Beat Q4 Earnings on Growing Occupancy?
by Zacks Equity Research
CYH's fourth-quarter earnings are likely to have been aided by higher revenue per adjusted admission.
Tenet Q4 Earnings Beat Estimates on Favorable Payer Mix
by Zacks Equity Research
THC expects net operating revenues between $20.6 billion and $21 billion in 2025.
Why HCA Healthcare (HCA) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Encompass Health Q4 Earnings Beat on Strong Discharge Growth
by Zacks Equity Research
EHC expects adjusted EPS from continuing operations in the range of $4.67-$4.96 in 2025.
Can Tenet Healthcare Navigate Through Lower Revenues in Q4?
by Zacks Equity Research
THC's fourth-quarter results are likely to reflect growing patient admissions, utilization and patient days.
Ensign Group Shares Plunge 12% Despite Q4 Earnings Beat
by Zacks Equity Research
ENSG's fourth-quarter results gain on strong contribution from the Skilled Services unit, partly offset by the escalating cost of services. It estimates 2025 adjusted EPS to be within $6.16-$6.34.
Earnings Growth & Price Strength Make HCA Healthcare (HCA) a Stock to Watch
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Centene Q4 Earnings Beat Estimates on Membership Growth, 2025 View Up
by Zacks Equity Research
CNC now projects premium and service revenues of $158-$160 billion in 2025.
Zacks Industry Outlook Highlights HCA Healthcare, Tenet Healthcare, Universal Health, Acadia Healthcare and Community Health
by Zacks Equity Research
HCA Healthcare, Tenet Healthcare, Universal Health, Acadia Healthcare and Community Health have been highlighted in this Industry Outlook article.
Thriving in Healthcare: 5 Hospital Stocks to Keep on Your Radar
by Kaibalya Pravo Dey
The Zacks Medical-Hospital industry is likely to benefit from improving financial, operating and staffing stability. Companies like HCA, THC, UHS, ACHC and CYH are well-positioned to gain from these trends.
Cigna Q4 Earnings Miss Estimates on Decline in Medical Membership
by Zacks Equity Research
CI's Q4 results reflect a decline in Individual and Family Plans customers. Management expects 2025 adjusted EPS at a minimum of $29.50, which indicates growth of at least 7.9% from the 2024 figure.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why HCA Healthcare (HCA) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why HCA Healthcare (HCA) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
New to Investing? This 1 Medical Stock Could Be the Perfect Starting Point
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
HCA Healthcare's Q4 Earnings Beat Estimates on Strong Admissions
by Zacks Equity Research
HCA's Q4 results benefit from improved equivalent admissions and inpatient surgeries, partly offset by the impact of hurricanes and higher salaries and benefits expenses.
Compared to Estimates, HCA (HCA) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for HCA (HCA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.